Table 2 Treatment patterns and disease courses of new-onset SJIA in Germany
Database | National pediatric rheumatology database (2011–2013) | ICON-JIA (2010–2015) | AID registry (2008–2015) |
|---|---|---|---|
Number SJIA patients | 125 | 34 | 251 |
Initial pharmacologic treatments | |||
 Timeframe assessed | Patients with disease duration of 12 months or less | At time of enrollment (within 12 months of disease onset) and within three months prior | In the first three months of treatment |
NSAIDs | 55 (44.0%) | 29 (85.3%) | 145 (57,8%) |
Systemic glucocorticoids | 75 (60.0%) | 33 (97.1%) | 178 (70.9%) |
Intraarticular glucocorticoids | 6 (4.8%) | 4 (11.8%) | N/A |
 Methotrexate | 68 (54.4%) | 16 (47.1%) | 102 (40.6%) |
 Anakinra | 17 (13.6%) | 5 (14.7%) | 31 (12.4%) |
 Canakinumab | 5 (4.0%) | 2 (5.9%) | 7 (2.8%) |
 Tocilizumab | 12 (9.6%) | 2 (5.9%) | 12 (4.8%) |
 Adalimumab | 1 (0.8%) | 0 (0%) | 0 (0%) |
 Etanercept | 2 (1.6%) | 1 (2.9%) | 6 (2.4%) |
 Cyclosporin A | 0 (0%) | 1 (2.9%) | 0 (0%) |
Disease course | N/A | Inactive disease: 3Â months: 56% 6Â months: 64% 9Â months: 70% 12Â months: 70% 18Â months: 68% 24Â months: 80% | Sufficient data for 156 pts.: Monocyclic 42 (26.9%) Polycyclic 62 (39.7%) Chronic 52 (33.3%) Among 108 pts. with arthritis: Monocyclic 19 (17.6%) Polycyclic 39 (36.1%) Chronic 50 (46.2%) |